MME and neoplasm: Another interesting point is the favorable increase in tumor uptake in the Entresto® group (Table 4, to 11.57 ± 1.92%IA/g; p < 0.0001), emphasizing the positive effect of in situ NEP inhibition not only on the stability of both radiopeptides but on their tumor targeting at a later time point as well, as previously reported for a series of NEP-biodegradable peptide radioligands [25].